2. Search Result
Search Result
Results for "

Chronic Pain

" in MedChemExpress (MCE) Product Catalog:

91

Inhibitors & Agonists

2

Screening Libraries

10

Peptides

1

Inhibitory Antibodies

6

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152190
    JB002

    		Myosin Cardiovascular Disease
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB002
  • HY-P99221
    Tanezumab

    RN-624; PF 4383119

    		 Trk Receptor Neurological Disease Inflammation/Immunology Cancer
    Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
    Tanezumab
  • HY-103550
    A-841720

    		mGluR Neurological Disease
    A-841720 is a potent, non-competitive and selective mGlu1 receptor antagonist with an IC50 of 10 nM for human mGlu1 receptor. A-841720 displays 34-fold selectivity over mGlu5 (IC50 of 342 nM), and no significant activity at a range of other neurotransmitter receptors, ion channels, and transporters. A-841720 has the potential for chronic pain research .
    A-841720
  • HY-110292
    A-425619

    		TRP Channel Inflammation/Immunology
    A-425619, a potent and selective TRPV1 receptor antagonist, is effective in alleviating acute and chronic inflammatory pain and postoperative pain .
    A-425619
  • HY-162244
    COX-2-IN-40

    		COX Inflammation/Immunology
    COX-2-IN-40 (compound 17) is a COX-2 inhibitor with the IC50 of 14.86 μM. COX-2-IN-40 can be used for study of chronic pain .
    COX-2-IN-40
  • HY-159094
    Nav1.8-IN-15

    		Sodium Channel Neurological Disease
    Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .
    Nav1.8-IN-15
  • HY-P5907
    Helianorphin-19

    		Opioid Receptor Neurological Disease
    Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a Ki of 21 nM and an EC50 of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain .
    Helianorphin-19
  • HY-117683
    BCTP

    		TRP Channel Neurological Disease
    BCTP is a TRPV1 antagonist. BCTP activated at low pH showed functional antagonist activity against human TRPV1 in CHO cells (IC50=18 nM). BCTP can be used in the study of chronic pain .
    BCTP
  • HY-P5153
    ProTx-III

    μ-TRTX-Tp1a

    		 Sodium Channel Neurological Disease
    ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Nav1.7, with an IC50 of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .
    ProTx-III
  • HY-P5857
    MmTx2 toxin

    Micrurotoxin 2

    		 GABA Receptor Neurological Disease
    MmTx2 toxin is a GABAA receptor modulator that enhances GABAA receptor sensitivity to agonists. MmTx2 toxin can be obtained from venom of coral snake. MmTx2 toxin can be used in the study of neurological diseases such as epilepsy, schizophrenia and chronic pain .
    MmTx2 toxin
  • HY-110358
    QAQ dichloride

    		Sodium Channel Inflammation/Immunology
    QAQ dichloride, a photoswitchable voltage-gated Nav and Kv channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form. QAQ dichloride is membrane-impermeant and only infiltrates pain-sensing neurons that express endogenous import channels. QAQ dichloride acts as a light-sensitive analgesic and can be used for studying of signaling mechanisms in acute and chronic pain .
    QAQ dichloride
  • HY-138761
    EP4 receptor antagonist 3

    		Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4 receptor antagonist 3 is a potent EP4 receptor antagonist, example 3,extracted from patent WO2010019796 A1. EP4 receptor antagonist 3 can be used for the reseacrh of EP4 receptor-mediated diseases, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer .
    EP4 receptor antagonist 3
  • HY-110358A
    QAQ

    		Sodium Channel Inflammation/Immunology
    QAQ dichloride dichloride, a photoswitchable voltage-gated Nav and Kv channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form. QAQ dichloride dichloride is membrane-impermeant and only infiltrates pain-sensing neurons that express endogenous import channels. QAQ dichloride dichloride acts as a light-sensitive analgesic and can be used for studying of signaling mechanisms in acute and chronic pain .
    QAQ
  • HY-108449
    Acoltremon
    1 Publications Verification

    WS-12; AR-15512; AVX-012

    		 TRP Channel Cancer
    Acoltremon (WS-12; AR-15512) is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .
    Acoltremon
  • HY-19589
    JTS-653

    		TRP Channel Neurological Disease Inflammation/Immunology
    JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents .
    JTS-653
  • HY-110237
    BX430

    		P2X Receptor Calcium Channel Cardiovascular Disease
    BX430 is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.
    BX430
  • HY-167855
    MRS4833

    		P2Y Receptor Inflammation/Immunology
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
    MRS4833
  • HY-145604
    Vicasinabin

    RG7774

    		 Cannabinoid Receptor Neurological Disease
    Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1) .
    Vicasinabin
  • HY-163476
    PIP5K1C-IN-1

    		Others Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-122001
    PF-05186462

    		Sodium Channel Neurological Disease
    PF-05186462 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channel, with an IC50 of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .
    PF-05186462
  • HY-119097
    LY456066

    		mGluR Neurological Disease
    LY456066 is a selective non-competitive metabotropic glutamate receptors (mGluR1) antagonist with an IC50 value of 52.0 nM. LY456066 is effective in rodent models of anxiolysis and nociception. LY456066 reduces hyperalgesia and the amount of licking and flinching following formalin injection, which is promising for research of analgesics for chronic pain .
    LY456066
  • HY-152206
    JB062

    		Myosin Neurological Disease
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB062
  • HY-17474
    Parecoxib
    1 Publications Verification

    SC 69124

    		 COX Inflammation/Immunology Cancer
    Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib
  • HY-17474A
    Parecoxib Sodium
    1 Publications Verification

    SC 69124A

    		 COX Inflammation/Immunology Cancer
    Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib Sodium
  • HY-118858
    UCPH-102

    		EAAT Neurological Disease Cancer
    UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder .
    UCPH-102
  • HY-17474AR
    Parecoxib Sodium (Standard)

    		COX Inflammation/Immunology Cancer
    Parecoxib (Sodium) (Standard) is the analytical standard of Parecoxib (Sodium). This product is intended for research and analytical applications. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib Sodium (Standard)
  • HY-17474R
    Parecoxib (Standard)

    		COX Inflammation/Immunology Cancer
    Parecoxib (Standard) is the analytical standard of Parecoxib. This product is intended for research and analytical applications. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib (Standard)
  • HY-P1626
    Acetyl tetrapeptide-15

    		Opioid Receptor Neurological Disease
    Acetyl tetrapeptide-15 is a synthetic peptide used in the cosmetics for sensitive skin. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioid receptor via an endorphin-like pathway .
    Acetyl tetrapeptide-15
  • HY-N0388
    Gelsemine

    		Others Neurological Disease
    Gelsemine, an alkaloid from the Chinese herb Gelsemium elegans, is effective in mitigating chronic pain. Antinociceptive effects.
    Gelsemine
  • HY-14777
    Radiprodil

    RGH-896

    		 iGluR Neurological Disease
    Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions .
    Radiprodil
  • HY-107527A
    Org 25543

    		Others Inflammation/Immunology
    Org 25543 is a selective inhibitor of the glycine transporter 2, exhibiting analgesic properties in a rat model of chronic pain.
    Org 25543
  • HY-123374
    (Rac)-AMG 628

    		TRP Channel Neurological Disease
    (Rac)-AMG 628 is the racemate of AMG 628, a potent TRPV1 antagonist with an IC50 of 3.7nM. AMG 628 can be used in chronic pain research .
    (Rac)-AMG 628
  • HY-148708
    Oleoyl-D-lysine

    		iGluR Neurological Disease
    Oleoyl-D-lysine is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine reverses neuropathic pain in mice, shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine is safe and effective without respiratory depression .
    Oleoyl-D-lysine
  • HY-14909
    Bardoxolone
    Maximum Cited Publications
    15 Publications Verification

    CDDO; RTA 401

    		 Keap1-Nrf2 Necroptosis Metabolic Disease Cancer
    Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .
    Bardoxolone
  • HY-B0405S
    Bupivacaine-d9

    		Isotope-Labeled Compounds iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease
    Bupivacaine-d99 is a deuterium labeled Bupivacaine. Bupivacaine is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain[1][2][3].
    Bupivacaine-d9
  • HY-P0062
    Ziconotide

    SNX-111

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide
  • HY-P0062B
    Ziconotide acetate

    SNX-111 acetate

    		 Calcium Channel Cardiovascular Disease Inflammation/Immunology Cancer
    Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide acetate
  • HY-N0388R
    Gelsemine (Standard)

    		Others Neurological Disease
    Gelsemine (Standard) is the analytical standard of Gelsemine. This product is intended for research and analytical applications. Gelsemine, an alkaloid from the Chinese herb Gelsemium elegans, is effective in mitigating chronic pain. Antinociceptive effects.
    Gelsemine (Standard)
  • HY-14466
    GW 848687X

    		Prostaglandin Receptor Endocrinology
    GW 848687X is a selective, orally active prostaglandin EP1 receptor antagonist for the inhibition of inflammatory pain. The oral bioavailability of GW 848687X was 54% in rats and 53% in dogs. GW 848687X has a half-life of 2 hours and has inhibitory potential for both acute and chronic pain .
    GW 848687X
  • HY-111258
    GSK345931A

    		Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    GSK345931A is an EP1 receptor antagonist. GSK345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain .
    GSK345931A
  • HY-120751
    TROX-1

    		Calcium Channel Neurological Disease
    TROX-1 is an N-type calcium channel (CaV2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 can be used in chronic pain research .
    TROX-1
  • HY-P0062A
    Ziconotide TFA

    SNX-111 TFA

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide TFA
  • HY-150270
    NP-1815-PX

    		P2X Receptor Neurological Disease Inflammation/Immunology
    NP-1815-PX is a potent and selective P2X4R antagonist. NP-1815-PX has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions .
    NP-1815-PX
  • HY-150270A
    NP-1815-PX sodium

    		P2X Receptor Neurological Disease Inflammation/Immunology
    NP-1815-PX sodium is a potent and selective P2X4R antagonist. NP-1815-PX sodium has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX sodium also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions .
    NP-1815-PX sodium
  • HY-B0405A
    Bupivacaine hydrochloride
    2 Publications Verification

    		 iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease Cancer
    Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain .
    Bupivacaine hydrochloride
  • HY-B0405
    Bupivacaine
    2 Publications Verification

    		 iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease Cancer
    Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain .
    Bupivacaine
  • HY-W415121
    Bupivacaine hydrochloride monohydrate

    		iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease Cancer
    Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain .
    Bupivacaine hydrochloride monohydrate
  • HY-W709349
    Flupirtine hydrochloride

    D 9998 hydrochloride

    		 Potassium Channel iGluR Inflammation/Immunology
    Flupirtine hydrochloride (D 9998 hydrochloride) is a selective neuropotassium channel opener with analgesic activity. Flupirtine hydrochloride is used to inhibit a variety of pain conditions, including chronic musculoskeletal pain, migraines, and neuralgia. Flupirtine hydrochloride has antidepressant and antioxidant properties and may increase the analgesic effect in combination therapy with morphine. Flupirtine hydrochloride relieves abnormally increased muscle tension and has a muscle relaxant effect. Flupirtine hydrochloride is clinically superior to other drugs, such as tramadol and pantoxan, plus its side effects are better tolerated. Flupirtine hydrochloride has a significant effect on inhibiting neural hyperexcitability and therefore exhibits inhibitory potential in various pain states .
    Flupirtine hydrochloride
  • HY-168166
    CHET3

    		Others Neurological Disease
    CHET3 is a sex-selective activator with potent analgesic activity. CHET3 was discovered to be a highly selective omnidirectional modulator of TASK-3-containing K2P channels, including TASK-3 homologues and TASK-3/TASK-1 heterologues. CHET3 exhibited significant analgesic effects in multiple acute and chronic pain models in mice, which could be abolished by pharmacological means or genetic knockout of TASK-3. CHET3 is able to functionally modulate the membrane excitability of specific small sensory neurons, which supports its analgesic effects on thermal hypersensitivity and mechanical hyperalgesia in chronic pain .
    CHET3
  • HY-P10767
    MD01-67

    		Neurotensin Receptor Neurological Disease
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models .
    MD01-67

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: